BPDCN is an aggressive type of blood cancer that originates from plasmacytoid dendritic cells (pDCs), a component of the immune system that produces type 1 interferon cytokines. These cytokines ...

Historically, BPDCN treatment relied on chemotherapy regimens adapted from leukemia or lymphoma protocols. However, recent breakthroughs have transformed the treatment paradigm. ELZONRIS (Stemline ...

Stemline also commercializes tagraxofusp-erzs, a novel targeted therapy directed to CD123, for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic cancer ...

About BPDCN BPDCN, formerly blastic NK-cell lymphoma ... lymph nodes and viscera. The BPDCN cell of origin is the plasmacytoid dendritic cell (pDC) precursor. The diagnosis of BPDCN is based ...

About ELZONRIS® (Tagraxofusp-erzs) U.S. Indication: ELZONRIS is a prescription medicine used to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and pediatric patients 2 years ...

You have permission to edit this article. Edit Close Activate Subscribe My Account Logout Login/Register ...

VisualDx is a clinical decision support system used by more than 2,300 hospitals, clinics, and medical schools around the world VisualDx's system seeks to enhance identification of people who may ...